According to the Zhitong Finance App, Baiben Healthcare (02293) announced its interim results announcement for the six months ending December 31, 2022. The company achieved revenue of HK$67.7 million, a decrease of about 7.2% over the previous year; profit attributable to shareholders of HK$30.6 million, a decrease of about 8.7% over the previous year; profit of 7.65 Hong Kong cents per share and an interim dividend of HK$3.75 per common share.
According to the announcement, revenue from providing services related to outreach case assessment fell by about HK$16.6 million to about HK$4.2 million during the period, mainly due to reduced demand for medical and health assessment services (particularly community vaccination centres in Hong Kong, China).